Delivery of drugs

Ijeoma Uchegbu; Andreas G. Schätzlein; Lisa Godfrey; Katerina Lalatsa; Antonio Ianitelli

Delivery of drugs

Ijeoma Uchegbu (Inventor), Andreas G. Schätzlein (Inventor), Lisa Godfrey (Inventor), Katerina Lalatsa (Inventor), Antonio Ianitelli (Inventor)

Strathclyde Institute Of Pharmacy And Biomedical Sciences

Research output: Patent

Abstract

The present invention relates to a composition comprising a hydrophilic drug and an amphiphilic carbohydrate compound for use in therapy wherein the composition is intranasally administered to the human or animal body. The composition can be used to treat a variety of disorders, including schizophrenia, obesity, pain and sleep disorders, psychiatric diseases, neurodegenerative conditions, brain cancers and infective diseases

Original language	English
Patent number	WO/2015/063510
IPC	A61K47/36 2006.1,A61K 38/08/2006.1
Priority date	4/11/13
Filing date	3/11/14
Publication status	Published - 7 May 2015

Keywords

intranasal delivery
intranasal administration of drugs
blood brain barrier
hydrophilic drug
amphiphilic carbohydrate compound

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

https://patentscope.wipo.int/search/en/detail.jsf?docId=WO2015063510&recNum=1&office=&queryString=FP%3A%28lalatsa%29&prevFilter=&sortOption=Pub+Date+Desc&maxRec=6Licence: Unspecified

Cite this

@misc{3251b994d5f2417b824e67997b64b756,

title = "Delivery of drugs",

abstract = "The present invention relates to a composition comprising a hydrophilic drug and an amphiphilic carbohydrate compound for use in therapy wherein the composition is intranasally administered to the human or animal body. The composition can be used to treat a variety of disorders, including schizophrenia, obesity, pain and sleep disorders, psychiatric diseases, neurodegenerative conditions, brain cancers and infective diseases",

keywords = "intranasal delivery, intranasal administration of drugs, blood brain barrier, hydrophilic drug, amphiphilic carbohydrate compound",

author = "Ijeoma Uchegbu and Sch{\"a}tzlein, {Andreas G.} and Lisa Godfrey and Katerina Lalatsa and Antonio Ianitelli",

note = "Classifications IPC A61K38/08; A61K47/36; CPC A61K38/08 (EP,US); A61K47/36 (EP,US); A61K9/0043 (EP,US); A61K9/0085 (US); A61K9/1652 (US); A61K9/5161 (EP,US); A61P25/00 (EP); A61P25/04 (EP); A61P25/18 (EP); A61P25/20 (EP); A61P3/04 (EP); A61P31/00 (EP); A61P35/00 (EP); A61K38/095 (EP,US); Priorities GB201319437A·2013-11-04; GB2014053254W·2014-11-03 Application CA2928697A·2014-11-03 Publication CA2928697A1·2015-05-07 Published as CA2928697A1;CA2928697C;EP3065779A1;EP3065779B1;JP2016539100A;JP6486349B2;US10213474B2;US2016279189A1;WO2015063510A1; WO/2015/063510; A61K47/36 2006.1,A61K 38/08/2006.1",

year = "2015",

month = may,

day = "7",

language = "English",

type = "Patent",

}

TY - PAT

T1 - Delivery of drugs

AU - Uchegbu, Ijeoma

AU - Schätzlein, Andreas G.

AU - Godfrey, Lisa

AU - Lalatsa, Katerina

AU - Ianitelli, Antonio

N1 - Classifications IPC A61K38/08; A61K47/36; CPC A61K38/08 (EP,US); A61K47/36 (EP,US); A61K9/0043 (EP,US); A61K9/0085 (US); A61K9/1652 (US); A61K9/5161 (EP,US); A61P25/00 (EP); A61P25/04 (EP); A61P25/18 (EP); A61P25/20 (EP); A61P3/04 (EP); A61P31/00 (EP); A61P35/00 (EP); A61K38/095 (EP,US); Priorities GB201319437A·2013-11-04; GB2014053254W·2014-11-03 Application CA2928697A·2014-11-03 Publication CA2928697A1·2015-05-07 Published as CA2928697A1;CA2928697C;EP3065779A1;EP3065779B1;JP2016539100A;JP6486349B2;US10213474B2;US2016279189A1;WO2015063510A1

PY - 2015/5/7

Y1 - 2015/5/7

N2 - The present invention relates to a composition comprising a hydrophilic drug and an amphiphilic carbohydrate compound for use in therapy wherein the composition is intranasally administered to the human or animal body. The composition can be used to treat a variety of disorders, including schizophrenia, obesity, pain and sleep disorders, psychiatric diseases, neurodegenerative conditions, brain cancers and infective diseases

AB - The present invention relates to a composition comprising a hydrophilic drug and an amphiphilic carbohydrate compound for use in therapy wherein the composition is intranasally administered to the human or animal body. The composition can be used to treat a variety of disorders, including schizophrenia, obesity, pain and sleep disorders, psychiatric diseases, neurodegenerative conditions, brain cancers and infective diseases

KW - intranasal delivery

KW - intranasal administration of drugs

KW - blood brain barrier

KW - hydrophilic drug

KW - amphiphilic carbohydrate compound

UR - https://patents.google.com/patent/WO2015063510A1/en?oq=WO%2f2015%2f063510

M3 - Patent

M1 - WO/2015/063510

Y2 - 2014/11/03

ER -

Delivery of drugs

Abstract

Keywords

UN SDGs

Access to Document

Other files and links

Fingerprint

Cite this